Perspective from Amelia Jernigan, MD
Source/Disclosures
Source: Lichter K, et al. Abstract 120. Presented at: Society of Gynecologic Cancer Annual Meeting; March 28-31, 2020 (virtual meeting).
Disclosures: Levinson reports no relevant financial disclosures. Please see the abstract for all other authors’ relevant financial disclosures.
April 13, 2020
2 min read
Save

Adjuvant HPV vaccination lowers risk for high-grade cervical dysplasia recurrence

Perspective from Amelia Jernigan, MD
Source/Disclosures
Source: Lichter K, et al. Abstract 120. Presented at: Society of Gynecologic Cancer Annual Meeting; March 28-31, 2020 (virtual meeting).
Disclosures: Levinson reports no relevant financial disclosures. Please see the abstract for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Kimberly L. Levinson, MD
Kimberly L. Levinson

Women who received the HPV vaccine after surgical excision for high-grade cervical dysplasia had lower risk for recurrence than women who received placebo or surgery alone, according to results of a systemic review and meta-analysis presented at the virtual Society of Gynecologic Cancer Annual Meeting.

“Our findings are important because they suggest there is a significant association with HPV vaccination at the time of surgical resection for dysplasia and a reduction in the risk for recurrence,” Kimberly L. Levinson, MD, director of gynecologic oncology at Johns Hopkins University School of Medicine, told Healio. “Recurrent cervical dysplasia is concerning for multiple reasons. One concern is for progression to an invasive cancer. [HPV vaccination] also may have significant clinical benefit, as women with recurrent disease require multiple examinations and procedures — many of which could be prevented or decreased with lowered risk for recurrence.”

Levinson and colleagues pooled data from six studies published between 1990 and 2019 that included 2,984 women with cervical intraepithelial neoplasia grade 1 or higher, CIN grade 2 or higher, or HPV 16/18-associated CIN.

Researchers compared recurrence rates of 1,360 women who received HPV vaccination after surgical excision for recurrent cervical dysplasia with those of 1,624 women who received placebo or surgery alone. Follow-up was between 6 months and 48 months.

Women who received the HPV vaccine after surgical excision for high-grade cervical dysplasia had lower risk for recurrence than women who received placebo or surgery alone

Overall, 3.3% (n = 99) of women experienced recurrence of CIN grade 2 or higher. However, risk appeared lower among women who received adjuvant HPV vaccination (1.7% vs. 4.7%; RR = 0.34; 95% CI, 0.22-0.55). Researchers also observed lower risk for recurrence among vaccinated women with CIN grade 1 or higher (6.3% vs. 9.7%; RR = 0.67; 95% CI, 0.52-0.85).

Among four studies that assessed recurrence of lesions specific to HPV strains 16/18, nine (0.9%) vaccinated women and 26 (2%) unvaccinated women experienced recurrence of HPV 16/18-associated CIN grade 2.

Moreover, 49 women developed recurrent HPV 16/18-associated CIN grade 1, including 11 (1.1%) who received adjuvant vaccination and 38 (3.1%) who did not.

Researchers observed a statistically significant overall decreased risk for recurrent HPV 16/18-associated CIN grade 2 lesions (RR = 0.41; 95% CI, 0.2-0.85) and CIN grade 1 lesions (RR = 0.35; 95% CI, 0.18-0.67).

“There are currently two ongoing, large, randomized controlled trials that should help to better elucidate the benefit of adjuvant HPV vaccine in this setting,” Levinson told Healio. “Our group has a strong interest in prevention and treatment of cervical cancers, and we will continue to conduct extensive research in this area.” – by Jennifer Southall

Reference:

Lichter K, et al. Abstract 120. Presented at: Society of Gynecologic Cancer Annual Meeting; March 28-31, 2020 (virtual meeting).

Disclosures: Levinson reports no relevant financial disclosures. Please see the abstract for all other authors’ relevant financial disclosures.